(Q46358244)

English

Addition of risperidone to sertraline improves sertraline-resistant refractory depression without influencing plasma concentrations of sertraline and desmethylsertraline

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18803170

Addition of risperidone to sertraline improves sertraline-resistant refractory depression without influencing plasma concentrations of sertraline and desmethylsertraline (English)

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18803170

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Wakako Umene-Nakano

2

object named as

Wakako Umene-Nakano

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18803170

Reiji Yoshimura

1

object named as

Reiji Yoshimura

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18803170

6

object named as

Jun Nakamura

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18803170

Atsuko Ikenouchi-Sugita

4

object named as

Atsuko Ikenouchi-Sugita

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18803170

3

object named as

Nobuhisa Ueda

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18803170

5

object named as

Hikaru Hori

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18803170

publication date

1 December 2008

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18803170

Human Psychopharmacology

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18803170

23

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18803170

8

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18803170

707-713

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18803170

Risperidone for treatment-refractory major depressive disorder: a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FHUP.979

21 January 2018

Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FHUP.979

7 January 2021

based on heuristic

inferred from DOI database lookup

Dexamethasone augmentation in treatment-resistant depression

1 reference

https://api.crossref.org/works/10.1002%2FHUP.979

7 January 2021

based on heuristic

inferred from DOI database lookup

Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4

1 reference

https://api.crossref.org/works/10.1002%2FHUP.979

7 January 2021

based on heuristic

inferred from DOI database lookup

Risperidone in the treatment of psychotic depression

1 reference

https://api.crossref.org/works/10.1002%2FHUP.979

7 January 2021

based on heuristic

inferred from DOI database lookup

Human cytochromes mediating sertraline biotransformation: seeking attribution

1 reference

https://api.crossref.org/works/10.1002%2FHUP.979

7 January 2021

based on heuristic

inferred from DOI database lookup

A rating scale for depression

1 reference

https://api.crossref.org/works/10.1002%2FHUP.979

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparative study of sertraline dosages, plasma concentrations, efficacy and adverse reactions in Chinese versus Caucasian patients

1 reference

https://api.crossref.org/works/10.1002%2FHUP.979

7 January 2021

based on heuristic

inferred from DOI database lookup

Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets.

1 reference

https://api.crossref.org/works/10.1002%2FHUP.979

7 January 2021

based on heuristic

inferred from DOI database lookup

Extrapyramidal adverse effects associated with sertraline

1 reference

https://api.crossref.org/works/10.1002%2FHUP.979

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapeutic drug monitoring of sertraline: variability factors as displayed in a clinical setting

1 reference

https://api.crossref.org/works/10.1002%2FHUP.979

7 January 2021

based on heuristic

inferred from DOI database lookup

HPLC analysis of the second-generation antidepressant sertraline and its main metabolite N-desmethylsertraline in human plasma

1 reference

https://api.crossref.org/works/10.1002%2FHUP.979

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term efficacy and therapeutic drug monitoring of sertraline in major depression

1 reference

https://api.crossref.org/works/10.1002%2FHUP.979

7 January 2021

based on heuristic

inferred from DOI database lookup

Simplified high-performance liquid chromatographic method for determination of risperidone and 9-hydroxyrisperidone in serum from patients comedicated with other psychotropic drugs

1 reference

https://api.crossref.org/works/10.1002%2FHUP.979

7 January 2021

based on heuristic

inferred from DOI database lookup

Transport of brain-derived neurotrophic factor across the blood-brain barrier

1 reference

https://api.crossref.org/works/10.1002%2FHUP.979

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation

1 reference

https://api.crossref.org/works/10.1002%2FHUP.979

7 January 2021

based on heuristic

inferred from DOI database lookup

Plasma risperidone concentrations during combined treatment with sertraline.

1 reference

https://api.crossref.org/works/10.1002%2FHUP.979

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice

1 reference

https://api.crossref.org/works/10.1002%2FHUP.979

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19.

1 reference

https://api.crossref.org/works/10.1002%2FHUP.979

7 January 2021

based on heuristic

inferred from DOI database lookup

Population pharmacokinetic analysis of drug-drug interactions among risperidone, bupropion, and sertraline in CF1 mice

1 reference

https://api.crossref.org/works/10.1002%2FHUP.979

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of paroxetine or milnacipran on serum brain-derived neurotrophic factor in depressed patients

1 reference

https://api.crossref.org/works/10.1002%2FHUP.979

7 January 2021

based on heuristic

inferred from DOI database lookup

An open study of risperidone liquid in the acute phase of schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2FHUP.979

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of risperidone on plasma free 3-methoxy-4-hydroxyphenylglycol (pMHPG) levels in schizophrenic patients: relationship among plasma concentrations of risperidone and 9-hydroxyrisperidone, pMHPG levels, and clinical improvement

1 reference

https://api.crossref.org/works/10.1002%2FHUP.979

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of risperidone on plasma catecholamine metabolites and brain-derived neurotrophic factor in patients with bipolar disorders

1 reference

https://api.crossref.org/works/10.1002%2FHUP.979

7 January 2021

based on heuristic

inferred from DOI database lookup

Possible relationship between combined plasma concentrations of risperidone plus 9-hydroxyrisperidone and extrapyramidal symptoms. Preliminary study

1 reference

https://api.crossref.org/works/10.1002%2FHUP.979

7 January 2021

based on heuristic

inferred from DOI database lookup

Plasma levels of homovanillic acid and the response to risperidone in first episode untreated acute schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2FHUP.979

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhibitory effects of clozapine and other antipsychotic drugs on noradrenaline transporter in cultured bovine adrenal medullary cells.

1 reference

https://api.crossref.org/works/10.1002%2FHUP.979

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/HUP.979

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18803170

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18803170

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46358244&oldid=2108000056"